Ajanta Pharma Ltd
Ajanta Pharma Ltd (AJANTPHARM) last reported results for the quarter ended Jun 2026, with sales of ₹1,626 crore and net profit of ₹334 crore. The stock last traded at ₹3,529, a market capitalisation of ₹44,104 crore, on a P/E of 38.9. Over the past 52 weeks the stock has ranged between ₹2,380 and ₹3,797. Figures are as of 6 Oct 2026 and are not real time.
Ajanta Pharma Ltd share price and key metrics
- Current price
- ₹3,529
- Market cap
- ₹44,104 cr
- Stock P/E
- 38.9
- Book value
- ₹362
- ROE
- 27.1%
- ROCE
- 34.5%
- Dividend yield
- 0.91%
- 52w high / low
- 3797/2380
Metrics as of 6 Oct 2026. Not real time.
Track Ajanta Pharma Ltd
Cruxal reads every Ajanta Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Ajanta Pharma Ltd growth and returns
- 10 Years
- 12%
- 5 Years
- 14%
- 3 Years
- 13%
- TTM
- 20%
- 10 Years
- 10%
- 5 Years
- 12%
- 3 Years
- 24%
- TTM
- 22%
- 10 Years
- 10%
- 5 Years
- 18%
- 3 Years
- 26%
- 1 Year
- 43%
- 10 Years
- 23%
- 5 Years
- 23%
- 3 Years
- 25%
- Last Year
- 27%
Ajanta Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹1,626 cr, up 24.8% from ₹1,303 cr a year earlier. Net profit was ₹334 cr, up 31.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,187 | 1,146 | 1,170 | 1,303 | 1,354 | 1,375 | 1,422 | 1,626 |
| Expenses | 875 | 825 | 873 | 951 | 1,026 | 993 | 1,088 | 1,202 |
| Operating profit | 311 | 321 | 297 | 351 | 328 | 382 | 333 | 424 |
| OPM % | 26% | 28% | 25% | 27% | 24% | 28% | 23% | 26% |
| Other income | 19 | 30 | 18 | 26 | 59 | 25 | 61 | 71 |
| Interest | 6 | 8 | 6 | 5 | 3 | 5 | 2 | 3 |
| Depreciation | 34 | 36 | 40 | 41 | 43 | 44 | 45 | 44 |
| Profit before tax | 290 | 307 | 269 | 331 | 341 | 359 | 347 | 447 |
| Tax % | 25% | 24% | 16% | 23% | 24% | 24% | 23% | 25% |
| Net profit | 216 | 233 | 225 | 255 | 260 | 274 | 267 | 334 |
| EPS (₹) | 17.33 | 18.64 | 18.03 | 20.44 | 20.83 | 21.91 | 21.35 | 26.75 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Ajanta Pharma Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,983 | 2,126 | 2,055 | 2,588 | 2,890 | 3,341 | 3,743 | 4,209 | 4,648 | 5,453 | 5,776 |
| Operating profit | 691 | 658 | 567 | 683 | 1,001 | 933 | 808 | 1,172 | 1,269 | 1,500 | 1,467 |
| OPM % | 35% | 31% | 28% | 26% | 35% | 28% | 22% | 28% | 27% | 28% | 25% |
| Net profit | 507 | 469 | 387 | 468 | 654 | 713 | 588 | 816 | 920 | 1,056 | 1,135 |
| EPS (₹) | 38.40 | 35.50 | 29.56 | 35.73 | 50.38 | 55.63 | 45.89 | 63.70 | 73.68 | 84.52 | 90.84 |
TTM is the trailing twelve months to the most recent quarter.
Ajanta Pharma Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 18 | 18 | 18 | 18 | 17 | 17 | 25 | 25 | 25 | 25 |
| Reserves | 1,550 | 2,024 | 2,228 | 2,581 | 2,978 | 3,247 | 3,363 | 3,542 | 3,765 | 4,502 |
| Borrowings | 1 | 2 | 36 | 75 | 31 | 25 | 36 | 35 | 47 | 260 |
| Other liabilities | 254 | 383 | 383 | 619 | 702 | 711 | 1,159 | 927 | 1,067 | 1,250 |
| Total liabilities | 1,823 | 2,426 | 2,664 | 3,293 | 3,729 | 4,000 | 4,582 | 4,530 | 4,904 | 6,037 |
| Fixed assets | 589 | 1,053 | 1,178 | 1,472 | 1,541 | 1,512 | 1,496 | 1,479 | 1,762 | 1,867 |
| CWIP | 339 | 61 | 262 | 132 | 108 | 153 | 209 | 256 | 176 | 258 |
| Investments | 182 | 190 | 78 | 79 | 176 | 147 | 535 | 349 | 464 | 588 |
| Other assets | 713 | 1,122 | 1,147 | 1,610 | 1,904 | 2,188 | 2,341 | 2,446 | 2,502 | 3,324 |
| Total assets | 1,823 | 2,426 | 2,664 | 3,293 | 3,729 | 4,000 | 4,582 | 4,530 | 4,904 | 6,037 |
As reported by the company. Total assets equal total liabilities by construction.
Ajanta Pharma Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 609 | 281 | 375 | 457 | 576 | 562 | 792 | 785 | 1,157 | 529 |
| Cash from investing | -383 | -256 | -223 | -224 | -282 | -74 | -560 | 65 | -377 | -429 |
| Cash from financing | -202 | -0 | -147 | -129 | -318 | -460 | -108 | -1,051 | -733 | -168 |
| Net cash flow | 24 | 25 | 4 | 104 | -24 | 28 | 124 | -201 | 47 | -68 |
| Free cash flow | 313 | 19 | 32 | 228 | 417 | 431 | 618 | 646 | 840 | 169 |
| CFO / operating profit | 110% | 64% | 87% | 89% | 81% | 86% | 117% | 94% | 117% | 59% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Ajanta Pharma Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 46% | 34% | 24% | 27% | 32% | 29% | 23% | 32% | 32% | 35% |
| Debtor days | 59 | 79 | 82 | 109 | 93 | 111 | 103 | 108 | 93 | 124 |
| Inventory days | 186 | 315 | 415 | 276 | 434 | 347 | 283 | 283 | 308 | 289 |
| Days payable | 157 | 224 | 214 | 202 | 212 | 143 | 147 | 159 | 155 | 168 |
| Cash conversion cycle | 88 | 170 | 282 | 184 | 315 | 315 | 240 | 233 | 246 | 246 |
| Working capital days | 65 | 103 | 113 | 108 | 126 | 140 | 83 | 119 | 97 | 111 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Ajanta Pharma Ltd shareholding pattern
Promoters held 63.49% at Jun 2026, down from 66.26% at Jun 2025. FIIs 7.68% and DIIs 21.80%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 66.26% | 66.26% | 66.26% | 66.26% | 66.25% | 66.25% | 66.25% | 63.49% |
| FIIs | 9.11% | 9.26% | 8.86% | 8.86% | 8.53% | 7.97% | 8.26% | 7.68% |
| DIIs | 17.09% | 17.02% | 17.48% | 17.50% | 17.90% | 18.58% | 18.36% | 21.80% |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.00% |
| Public | 7.51% | 7.45% | 7.38% | 7.38% | 7.32% | 7.20% | 7.14% | 7.03% |
| No. of shareholders | 64,315 | 66,896 | 70,827 | 68,882 | 67,785 | 65,409 | 67,955 | 65,296 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Ajanta Pharma Ltd corporate filings
- Pls find enclosed Certificate as per Reg 74(5) of SEBI (DP) Regulations.Company Updatelow impact
- Promoter of Ajanta Pharma Limited pledges 4.6 lakh shares to issue NCDs, indicating potential short-term liquidity or financing activityInsider Trading / SASTmedium impact
Cruxal's analysis: Ajanta Pharma Limited's promoter, Aayush Agrawal, has created a pledge on 4.6 lakh equity…
Read the full analysis - Ajanta Pharma Pledges Shares to Secure Debentures Worth Rs 3,373 Crores, Indicating Significant Debt Financing ActivityInsider Trading / SASTmedium impact
Cruxal's analysis: Ajanta Pharma has disclosed a pledge of approximately 1.35 crore shares (around 10.8% of…
Read the full analysis - Ajanta Pharma submits FY 2026 Sustainability Report, no financial impact indicatedCompany Updatelow impact
Cruxal's analysis: Ajanta Pharma Ltd filed its Sustainability Report for FY 2026 on September 30, 2026. The…
Read the full analysis - Ajanta Pharma Limited: Promoter releases pledge on 98,185 equity shares via loan repaymentInsider Trading / SASTmedium impact
Cruxal's analysis: Ajanta Pharma Limited has disclosed that the Aayush Agrawal Trust, a promoter entity, has…
Read the full analysis - Pls find enclosed herewith closure of trading window intimationInsider Trading / SASTlow impact
- Ajanta Pharma Limited: Promoter releases pledge on 17.36 lakh equity shares due to loan repaymentInsider Trading / SASTmedium impact
Cruxal's analysis: Ajanta Pharma Limited has announced that the Aayush Agrawal Trust, a promoter entity, has…
Read the full analysis - Ajanta Pharma Ltd announces participation in upcoming investor conferenceCompany Updatelow impact
Cruxal's analysis: Ajanta Pharma has filed an intimation regarding its participation in an investor…
Read the full analysis - Ajanta Pharma publishes newspaper notice regarding transfer of equity shares to IEPFCompany Updatelow impact
Cruxal's analysis: Ajanta Pharma has issued a mandatory newspaper publication regarding the transfer of…
Read the full analysis - Ajanta Pharma Limited: Promoter Entity Discloses Simultaneous Release and Creation of Share PledgesInsider Trading / SASTlow impact
Cruxal's analysis: Ajanta Pharma Limited has reported a routine promoter-level transaction involving the…
Read the full analysis - Ajanta Pharma Limited: Promoter releases pledge on 6,910 equity sharesInsider Trading / SASTlow impact
Cruxal's analysis: Ajanta Pharma Limited has disclosed that promoter Ravi Agrawal (Trustee of Ravi Agrawal…
Read the full analysis - Ajanta Pharma Limited: Promoter Ravi Agrawal Releases Pledge on 54,796 Equity SharesInsider Trading / SASTmedium impact
Cruxal's analysis: Ajanta Pharma Limited has disclosed that promoter Ravi Agrawal (Trustee of Ravi Agrawal…
Read the full analysis - Ajanta Pharma Ltd announces participation in upcoming investor conferenceCompany Updatelow impact
Cruxal's analysis: Ajanta Pharma has issued a formal intimation regarding its participation in an investor…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.